Immunohistochemically detected IDH1 R132H mutation is rare and mostly heterogeneous in prostate cancer

Background IDH1 mutations are oncogenic through induction of DNA damage and genome instability. They are of therapeutic interest because they confer increased sensitivity to radiation and cytotoxic therapy and hold potential for vaccination therapy.